A Clinical Trial to Investigate the Safety and Efficacy of D-Mannose on Symptoms of Urinary Tract Infection in Women

NCT ID: NCT06719115

Last Updated: 2024-12-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-05-03
• Study Completion Date: 2024-06-20

Brief Summary

The objective of this acute study was to investigate the safety and efficacy of UClear for the resolution of urinary tract infection (UTI) symptoms in women. The main questions it aims to answer is:

1. Is there a difference in proportion of participants with complete resolution of UTI symptoms at Day 4 between UClear and placebo

2. Is there a difference in change from baseline (Day 1) at Day 4 between UClear and placebo in Urinary Tract Infection Symptom Assessment (UTISA) symptom severity scores.

Participants will take UClear or placebo twice a day for 3 days with or without food, have 4 in clinical visits, and will be instructed to complete a quality of life (QoL) questionnaire during each visit and a UTISA questionnaire at follow-up (Day 7).

Conditions

Urinary Tract Infection(UTI)

Keywords

Uncomplicated urinary tract infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

UClear

UClear contains 1.5g of D-Mannose. Participants will be instructed to take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit). The product should be completely dissolved in a full glass of water and participants are instructed to take one dose in the morning and one dose in the afternoon. If a dose was missed participants were instructed to take the missed dose as soon as they remembered. Participants were advised not to exceed two doses daily.

Group Type: EXPERIMENTAL

UClear

Intervention Type: DIETARY_SUPPLEMENT

Take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).

Placebo

Participants will be instructed to take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).The product should be completely dissolved in a full glass of water and participants are instructed to take one dose in the morning and one dose in the afternoon. If a dose was missed participants were instructed to take the missed dose as soon as they remembered. Participants were advised not to exceed two doses daily.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).

Interventions

UClear

Take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).

Intervention Type: DIETARY_SUPPLEMENT

Placebo

Take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Females between 18 and 75 years of age, inclusive, at screening
• Individuals not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,

Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

• Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
• Double-barrier method
• Intrauterine devices
• Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
• Vasectomy of partner at least 6 months prior to screening

• At least two uncomplicated UTI symptoms defined by frequent, urgent, and painful urination, incomplete voiding, pelvic and low back pain, and blood in urine, as assessed by UTISA questionnaire
• Positive urine dip stick test for nitrites or leukocytes
• Agree to keep lifestyle, including dietary habits, physical activity patterns, and medications/supplements, consistent for the duration of the trial
• Provided voluntary, written, informed consent to participate in the study

Exclusion Criteria

• Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
• Allergy, sensitivity, or intolerance to the investigational product, placebo, or rescue medication ingredients
• Clinical signs and symptoms of an upper UTI (ex. costovertebral pain or tenderness, nausea, vomiting, fever), as assessed by the QI
• Anatomical or functional urinary tract abnormalities and/or diagnosis of kidney or other urinary tract diseases/conditions, such as painful bladder syndrome, neurogenic bladder, and polycystic kidney disease, as assessed by the QI
• History of or current urological cancers
• Current use of an indwelling catheter or intermittent catheterization
• Type I or Type II diabetes
• Unstable hypertension. Treatment on a stable dose of medication for at least three months will be considered by the QI
• Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least three months will be considered by the QI
• Self-reported confirmation of blood/bleeding disorders
• Individuals with an autoimmune disease or are immune compromised, as assessed by the QI
• Unstable metabolic disease or chronic diseases as assessed by the QI
• Current or history of any significant diseases of the gastrointestinal tract, as assessed by the QI
• History of or current diagnosis of liver diseases as assessed by the QI
• Participants who are within three days of the end of their menstruation, menstruating, or anticipating menstruation during the study
• Major surgery in the past three months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
• Current use of prescribed medications, over-the-counter (OTC) medications, or supplements, food/ drinks which may affect the efficacy and/or safety of the IP (see Sections 12.4.6 and 12.4.7)
• Use of medical cannabinoid products
• Use of cannabinoid products and is unwilling to stop use for the duration of the study
• Alcohol intake average of >2 standard drinks per day as assessed by the QI
• Alcohol or drug abuse within the last 12 months
• Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
• Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
• Individuals who are unable to give informed consent
• Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

KGK Science Inc.

INDUSTRY

Sponsor Role: collaborator

KEB Nutraceuticals USA, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David Crowley, MD

Role: PRINCIPAL_INVESTIGATOR

KGK Science Inc.

Locations

KGK Science Inc.

London, Ontario, Canada

Countries

Canada

Other Identifiers

22KBCFD01

Identifier Type: -

Identifier Source: org_study_id